Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precancerous Conditions 1Melanoma 1Inflammatory Bowel Diseases 1Hepatitis C 1Hematologic Neoplasms 1Granulomatous Disease, Chronic 1Fatigue 1Crohn Disease 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Infliximab × Clear all
NCT00112749 2020-07-31

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡